Molecular Response has introduced TargetX platform for the rapid discovery and validation of new oncology targets.
The integrated platform, which features 144,000 living tumor specimens, genomic databases and patient derived tumor models, will help drug development partners to minimise the research timelines.
Drug Design founder and Triphase Accelerator CSO Dr. Mohit Trikha said that the TargetX is the largest scale genomic database matched to living patient-derived tumor models.
"We plan to access it for our drug pipeline development and biomarker identification; having everything in one place allows us to do in days what used to take months," Trikha added.
"Additionally, we can now work with living patient derived tumor samples rather than cultured cell lines."
Currently the database features cancer indications, namely colon carcinoma, NSCLC, melanoma, ovarian carcinoma, prostate cancer and Non-Hodgkins Lymphoma.
Molecular Response CSO Thomas Broudy said that the company continues to focus on the use of patient derived models, for advancing oncology drug development.
"Everybody would like to perform studies in the patient derived tumor setting starting as early as possible, but without the resource to do so, it's nearly impossible. TargetX now enables you to do that," Broudy added.